secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001437749-25-002935
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends PDUFA date for Eton's ET-400 NDA to May 28, 2025
------------------------------------------------------------

- Original PDUFA date Feb 28, 2025 extended 3 months to May 28, 2025 for FDA review of supplemental info submitted Dec 2024.
- Eton states it has fully addressed all FDA questions and there are no outstanding requests.
- CEO says standard extension will not significantly affect internal 2025 revenue projections; company remains confident.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/0001437749-25-002935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925002935/eton20250205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-002935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer